<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954484</url>
  </required_header>
  <id_info>
    <org_study_id>190514</org_study_id>
    <nct_id>NCT02954484</nct_id>
  </id_info>
  <brief_title>Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty</brief_title>
  <official_title>Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to provide high quality evidence from a double-blinded, randomized controlled
      trial on the efficacy of perioperative pregabalin in reducing morphine requirements,
      improving pain scores and reducing chronic neuropathic pain when compared with placebo for
      primary total knee arthroplasty. It hence aims to improve on choice of analgesia adjuncts for
      total knee arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims:

      Whether pregabalin given preoperatively and for one week postoperatively in addition to
      patient-controlled analgesia (PCA) morphine is effective in reducing morphine requirements,
      improving pain scores and reducing chronic neuropathic pain when compared with placebo for
      primary total knee arthroplasty.

      Methodology:

      A single-centre double-blind randomized controlled trial in patients undergoing primary total
      knee arthroplasty. All subjects receive PCA morphine, paracetamol 1g every six hours,
      etoricoxib 120mg once daily postoperatively. Subjects receive either pregabalin 75mg po
      preoperatively followed by 75mg OM and 25mg ON for two days postoperatively or matching
      placebo. The primary outcome is cumulative morphine consumption at 72 hr following surgery.
      Secondary outcome measures included pain scores, knee range of motion and patient
      satisfaction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative morphine consumption at 72 hours postoperatively</measure>
    <time_frame>72 hours postoperatively</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional scores: SF-36v2 at 3 months and 6 months postoperatively</measure>
    <time_frame>3 months and 6 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional scores: Knee Society Score at 3 months and 6 months postoperatively</measure>
    <time_frame>3 months and 6 months postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional scores: WOMAC at 3 months and 6 months postoperatively</measure>
    <time_frame>3 months and 6 months postoperatively</time_frame>
    <description>Western Ontario and McMaster Universities Arthritis Index (WOMAC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee range of motion at 3 months and 6 months postoperatively</measure>
    <time_frame>3 months and 6 months postoperatively</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>PREGABALIN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive pregabalin 75mg orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive either placebo tablet (of identical appearance to pregabalin) orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin</intervention_name>
    <description>see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.</description>
    <arm_group_label>PREGABALIN</arm_group_label>
    <other_name>Lyrica (Pfizer Pte Ltd, Singapore)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule containing lactose and MCC (no active ingredients).</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>Manufactured by Beacons Pharmaceuticals Pte Ltd, Singapore.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib</intervention_name>
    <description>Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore</description>
    <arm_group_label>PREGABALIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>'Arcoxia'</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paracetamol</intervention_name>
    <description>Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia</description>
    <arm_group_label>PREGABALIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.
Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany</description>
    <arm_group_label>PREGABALIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden</description>
    <arm_group_label>PREGABALIN</arm_group_label>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>'Naropin'</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing primary total knee arthroplasty

        Exclusion Criteria:

          -  revision or bilateral arthroplasty, significant renal or hepatic impairment,
             documented allergy or intolerance to NSAIDs, paracetamol, morphine or pregabalin,
             chronic pain syndrome treated with chronic opioids, obstructive sleep apnea not
             treated with continuous positive airway pressure, seizures, breastfeeding, inability
             to use patient-controlled analgesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lingaraj krishna, frcs (Orth)</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Health System, Singapore</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Etoricoxib</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

